Imugene Limited (IUGNF)
USD 0.02
(-23.91%)
USD 0.02
(-23.91%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 1.54 Million AUD | 179.5% |
| 2023 | 553.47 Thousand AUD | -17.81% |
| 2022 | 673.43 Thousand AUD | 148.47% |
| 2021 | 271.02 Thousand AUD | 290.89% |
| 2020 | 69.33 Thousand AUD | -43.58% |
| 2019 | 122.89 Thousand AUD | 0.0% |
| 2018 | - AUD | 0.0% |
| 2017 | - AUD | 0.0% |
| 2016 | - AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| 2006 | - AUD | 0.0% |
| 2005 | - AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | -100.0% |
| 2001 | 1.21 Million AUD | 326.48% |
| 2000 | 285 Thousand AUD | 18.26% |
| 1999 | 241 Thousand AUD | -60.1% |
| 1998 | 604 Thousand AUD | 7.09% |
| 1997 | 564 Thousand AUD | -18.61% |
| 1996 | 693 Thousand AUD | 10.88% |
| 1995 | 625 Thousand AUD | 1738.24% |
| 1994 | 34 Thousand AUD | -44.26% |
| 1993 | 61 Thousand AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.17 Million AUD | 0.0% |
| 2024 Q4 | 1.54 Million AUD | 0.0% |
| 2024 FY | 1.54 Million AUD | 179.5% |
| 2024 Q1 | 4.17 Million AUD | 520.53% |
| 2023 Q1 | - AUD | -100.0% |
| 2023 Q4 | 673.43 Thousand AUD | 85.82% |
| 2023 FY | 553.47 Thousand AUD | -17.81% |
| 2023 Q3 | 362.41 Thousand AUD | -15.26% |
| 2023 Q2 | 427.7 Thousand AUD | 0.0% |
| 2022 Q3 | 489.28 Thousand AUD | 0.0% |
| 2022 FY | 673.43 Thousand AUD | 148.47% |
| 2022 Q1 | - AUD | -100.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2022 Q4 | 673.43 Thousand AUD | 37.64% |
| 2021 Q1 | - AUD | -100.0% |
| 2021 Q4 | 271.02 Thousand AUD | 64.24% |
| 2021 FY | 271.02 Thousand AUD | 290.89% |
| 2021 Q2 | - AUD | 0.0% |
| 2021 Q3 | 165.02 Thousand AUD | 0.0% |
| 2020 Q3 | 8402.00 AUD | -77.24% |
| 2020 FY | 69.33 Thousand AUD | -43.58% |
| 2020 Q1 | 36.91 Thousand AUD | -69.97% |
| 2020 Q2 | 36.91 Thousand AUD | 0.0% |
| 2020 Q4 | 69.33 Thousand AUD | 725.23% |
| 2019 Q2 | 94.94 Thousand AUD | 0.0% |
| 2019 FY | 122.89 Thousand AUD | 0.0% |
| 2019 Q1 | 94.94 Thousand AUD | 0.0% |
| 2019 Q4 | 122.89 Thousand AUD | 91.11% |
| 2019 Q3 | 64.3 Thousand AUD | -32.27% |
| 2018 Q1 | - AUD | 0.0% |
| 2018 FY | - AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 Q3 | - AUD | 0.0% |
| 2018 Q2 | - AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 Q3 | - AUD | 0.0% |
| 2017 FY | - AUD | 0.0% |
| 2017 Q1 | - AUD | 0.0% |
| 2016 Q1 | - AUD | 0.0% |
| 2016 Q2 | - AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 FY | - AUD | 0.0% |
| 2016 Q3 | - AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2015 Q3 | - AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| 2014 Q1 | - AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | - AUD | 0.0% |
| 2005 FY | - AUD | 0.0% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | -100.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2001 FY | 1.21 Million AUD | 326.48% |
| 2001 Q4 | 1.21 Million AUD | 0.0% |
| 2000 Q4 | 285.72 Thousand AUD | 0.0% |
| 2000 FY | 285 Thousand AUD | 18.26% |
| 1999 Q4 | 241 Thousand AUD | 0.0% |
| 1999 FY | 241 Thousand AUD | -60.1% |
| 1998 FY | 604 Thousand AUD | 7.09% |
| 1997 Q4 | 564 Thousand AUD | 0.0% |
| 1997 FY | 564 Thousand AUD | -18.61% |
| 1996 FY | 693 Thousand AUD | 10.88% |
| 1995 FY | 625 Thousand AUD | 1738.24% |
| 1994 FY | 34 Thousand AUD | -44.26% |
| 1993 FY | 61 Thousand AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | 19.64% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 96.246% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -284.952% |
| SQZ Biotechnologies Company | 27.47 Million USD | 94.369% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 33.493% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 96.433% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 94.803% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -63.131% |
| Marizyme, Inc. | 18.71 Million USD | 91.735% |
| Genus plc | 233.1 Million USD | 99.336% |
| Pharming Group N.V. | 171.54 Million USD | 99.098% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -74.191% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -15.134% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -106.257% |
| ContraFect Corporation | 2.88 Million USD | 46.306% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -6.956% |
| IMV Inc. | 28.88 Million USD | 94.644% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 72.661% |
| ONE Bio Corp. | 19.71 Million USD | 92.154% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 97.309% |
| Mesoblast Limited | 118.7 Million USD | 98.697% |
| MultiCell Technologies, Inc. | 202.58 USD | -763512.894% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 95.327% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.63% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -145.514% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -25.934% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 62.471% |
| Biomind Labs Inc. | 735.54 Thousand USD | -110.311% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 48.882% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 88.098% |
| Skye Bioscience, Inc. | 4.61 Million USD | 66.482% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -330.048% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 47.211% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -993.096% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1041.753% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 73.652% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -5914.725% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -3.491% |
| Q BioMed Inc. | 4.1 Million USD | 62.362% |
| GB Sciences, Inc. | 1.75 Million USD | 12.072% |
| Alpha Cognition Inc. | 1.22 Million USD | -26.759% |
| CSL Limited | 12.18 Billion USD | 99.987% |
| Agentix Corp. | 50 Thousand USD | -2993.854% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 97.713% |
| Enzolytics Inc. | 996.33 Thousand USD | -55.261% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | 76.168% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -505.233% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 31.503% |
| argenx SE | 20 Million USD | 92.265% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 96.605% |
| HST Global, Inc. | 98.31 Thousand USD | -1473.375% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -521.955% |
| Halberd Corporation | 150 Thousand USD | -931.285% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 78.129% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -15028.87% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 42.89% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 35.484% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -574.657% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -940.623% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -671.089% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | 29.681% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 92.39% |
| Kadimastem Ltd | 891.22 Thousand USD | -73.573% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 67.166% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -518.321% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -4503.127% |
| Cell Source, Inc. | 9.25 Million USD | 83.284% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -104.565% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -104.565% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -219.426% |
| Itoco Inc. | 228.37 Thousand USD | -577.357% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -633.228% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 68.956% |
| International Stem Cell Corporation | 4.17 Million USD | 62.974% |
| CytoDyn Inc. | 30.07 Million USD | 94.857% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -339.659% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 80.218% |
| SYBLEU INC | 477.5 Thousand USD | -223.964% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1162.798% |
| Rebus Holdings, Inc. | 310 Thousand USD | -399.009% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 67.332% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2378.533% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 29.069% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 81.398% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 81.981% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 0.55% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -477.212% |
| Neutra Corp. | 54.15 Thousand USD | -2756.428% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 15.468% |
| PureTech Health plc | 25.51 Million USD | 93.936% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -26.36% |
| IXICO plc | 472.02 Thousand USD | -227.723% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 90.02% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 97.515% |
| CSL Limited | 12.18 Billion USD | 99.987% |
| Cellectis S.A. | 92.77 Million USD | 98.333% |